One Free Meal From Industry Ups Brand-Name Rx Among Doctors

This article originally appeared here.
Share this content:
One Free Meal From Industry Ups Brand-Name Rx Among Doctors
One Free Meal From Industry Ups Brand-Name Rx Among Doctors

MONDAY, June 20, 2016 (HealthDay News) -- Physicians who receive even one free meal, valued at less than $20 on average, are more likely to prescribe a promoted brand-name drug than a cheaper generic alternative, compared with doctors who did not accept a meal, according to a study published online June 20 in JAMA Internal Medicine.

University of California, San Francisco, researchers linked information from two federal databases. The team identified the most-prescribed brand-name drugs in each of four common drug classes in 2013. These included Forest Laboratories' Bystolic (nebivolol) and Daiichi Sankyo's Benicar (olmesartan medoxomil), as well as AstraZeneca's Crestor (rosuvastatin calcium) and Pfizer's Pristiq (desvenlafaxine succinate).

The researchers found 279,669 physicians received 63,524 payments totaling $1.4 million related to the four brand-name drugs. Ninety-five percent of payments were for meals, with an average cost of less than $20. Of those doctors, 155,849 wrote more than 20 prescriptions in at least one of the four categories. Even after adjusting for other factors like prescribing volume, doctors who received a single meal were more likely to prescribe Crestor over other statins, Bystolic over other β-blockers, Benicar over other angiotensin-converting enzyme inhibitors, and Pristiq over other antidepressants.

Payments for food and beverages provided to doctors totaled $224.5 million in 2014, JAMA Internal Medicine editor-at-large Robert Steinbrook, M.D., noted in an accompanying editorial. "If drug and device manufacturers were to stop sending money to physicians for promotional speaking, meals, and other activities without clear medical justification and invest more in independent bona fide research on safety, effectiveness, and affordability, our patients and the health care system would be better off," Steinbrook writes.

Abstract
Full Text
Editorial

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »